Core Viewpoint - Jiangsu Haooubo Biopharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Hunan Haooubo Biopharmaceutical Co., Ltd., has recently obtained three medical device registration certificates from the Hunan Provincial Drug Administration, enhancing its product offerings in the allergy testing market [1][2]. Group 1: Medical Device Registration - The company received three medical device registration certificates for allergy testing kits, which include: 1. A kit for quantitative detection of specific IgE antibodies for ragweed allergy [1]. 2. A kit for qualitative detection of specific IgE antibodies for food allergens [2]. 3. A kit for qualitative detection of specific IgE antibodies for inhalant allergens [2]. Group 2: Impact on the Company - The acquisition of these medical device registration certificates enriches the company's chemiluminescence platform testing menu, which is expected to enhance its market competitiveness and positively influence the sustainable development of the company and its subsidiaries [3].

Core Viewpoint - The company, Haobio, announced that its wholly-owned subsidiary, Hunan Haobio Pharmaceutical Co., Ltd., has received approval from the Hunan Provincial Drug Administration for three medical device registration certificates, enhancing its competitive position in the market [1] Group 1 - The approved medical devices include specific IgE antibody test kits for allergens: W22, food mixed FX5 (magnetic chemiluminescence method), and inhalant mixed SX (magnetic chemiluminescence method) [1] - The acquisition of these registration certificates will enrich the company's chemiluminescence platform testing menu, potentially improving its market competitiveness [1] - The actual sales performance will depend on future market expansion efforts, and the impact on the company's future performance remains unpredictable [1]